1. Home
  2. KRSP vs INDP Comparison

KRSP vs INDP Comparison

Compare KRSP & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rice Acquisition Corporation 3

KRSP

Rice Acquisition Corporation 3

N/A

Current Price

$10.39

Market Cap

486.7M

Sector

N/A

ML Signal

N/A

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

N/A

Current Price

$2.81

Market Cap

433.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KRSP
INDP
Founded
2025
2000
Country
United States
United States
Employees
N/A
5
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
486.7M
433.2M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
KRSP
INDP
Price
$10.39
$2.81
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
53.6K
★ 211.2K
Earning Date
01-01-0001
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.21
$0.92
52 Week High
$11.89
$5.96

Technical Indicators

Market Signals
Indicator
KRSP
INDP
Relative Strength Index (RSI) 39.82 44.77
Support Level $10.27 $2.66
Resistance Level $10.58 $2.96
Average True Range (ATR) 0.05 0.33
MACD -0.01 -0.05
Stochastic Oscillator 8.33 19.25

Price Performance

Historical Comparison
KRSP
INDP

About KRSP Rice Acquisition Corporation 3

Rice Acquisition Corp 3 is a blank check company.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: